Articles & Video
Interview: Promoting prosperity in the life science sectors of China and the UK
In this exclusive interview, Her Majesty’s Trade Commissioner for China at the Department for International Trade, John Edwards, discusses how China’s healthcare and life sciences markets are growing rapidly and are driven by increased demand and changes to regulations, plus much more.
Interview: Importance of diversity and partnering in global life sciences
ATLATL Innovation Cluster (IC) in the heart of Zhangjiang Pharma Valley. Its Founder and CEO, Dr. P.C. Zhu, designed it to be a launchpad for high-potential life sciences in China. In this interview with EBD Group he discusses the opportunities ATLATL provides and the importance of partnering in the life science industry.
Video Interview - Johnson & Johnson’s approach to external innovation
William N. Hait, MD, PhD, Global Head at Johnson & Johnson External Innovation gives an exclusive interview to Lucie Ellis, Executive Editor of In Vivo, Pharma Intelligence, ahead of ChinaBio® Partnering Forum Digital.
Interview – J&J’s multi-pronged approach to life science innovation, partnerships, and advanced technologies
Dr. Dan Wang, Head, Johnson & Johnson Innovation, Asia Pacific, and Dr. Sharon Chan, Head of JLABS @ Shanghai discuss its support of startups, interests in diverse disease areas, the importance of collaborations and much more in this exclusive interview with EBD Group.
Pharma R&D Annual Review 2020
The researchers and analysts at Pharma Intelligence have taken the guess work out of figuring out how pharmaceutical research and development has progressed over the past few years and what you can expect in 2020. Pharma R&D Annual Review 2020 condenses the thorough analysis of all drugs in development by pharmaceutical companies, from those at the preclinical stage, through the various stages of clinical testing and regulatory approval, and up to and including launch.
China's Challenges and Opportunities in the Wake of COVID-19
Discover how pharma companies in China are collaborating like never before to keep the supply chain from breaking, as well as asking the government to help address a flurry of issues laid bare by the public health crisis.
Interview- Roche’s approach to drug discovery, innovation and meeting patients' needs
James Sabry, Global Head of Roche Pharma Partnering, discusses Roche’s approach to discovering scientific breakthroughs, accelerating innovative research, collaborating with stakeholders, and meeting unmet medical needs in China and around the world.
Biopharma and Tech Innovators – Summer 2020
Download Xconomy and EBD Group’s new special report, Biopharma and Tech Innovators – Summer 2020, to learn more about the cutting-edge companies behind these innovations that are disrupting the sector and revolutionizing the healthcare landscape.
Latest Cancer Developments and Trends
Discover the latest trends and advancements in cancer treatment in this new article pack from Informa Pharma Intelligence. Inside this downloadable article pack you will discover what is driving oncology dealmaking in 2020.
Containing Coronavirus Through Innovation and Investment: An Xconomy Special Report
This report contains ideas, innovation, and experience from some of the major players at the forefront of efforts in combatting COVID-19. The exclusive articles were captured from the BIO-Europe Spring® event and are accompanied by some of the most pertinent stories from B2B publications Xconomy and Bioprocess Insider.
China Bio: Change and opportunity are constant
Rapid, unrelenting changes are altering China’s biotech landscape in 2020. Speakers at China Showcase in San Francisco last month focused on the fundamentals of this maturing market.
What's shaping the future of biotech?
Could the November presidential election impact drug prices? What does the investment landscape look like for this year? Download the free article pack to discover how financial and biotech experts tackled these questions and many more at Biotech Showcase™ and Digital Medicine & Medtech Showcase.
Tracking the Power of Presenting at Biotech Showcase
For the first time, Informa Pharma Intelligence explores the achievements by Biotech Showcase presenting companies, delving into the deal-making activity that has occurred for companies who have presented at the conference in the last five years.
Networking your way to the top, whether in North Face or Brooks Brothers
Timmerman selected Mount Kilimanjaro, a more achievable trek for most climbers, for his next philanthropic adventure, and invited members of the biotech community and employees of Fred Hutch to join him. On January 14, 2019, Timmerman will do a presentation on the Climb to Fight Cancer at Biotech Showcase™, from 4:15–5 pm, at the Parc 55 San Francisco Hotel.
The Power of Presenting at Biotech Showcase
Informa Pharma Intelligence analysts took a deep dive into what has happened to companies who have presented at Biotech Showcase. Since 2015, over 250 companies that have presented at Biotech Showcase have generated deals worth over $61bn.
Giving a Pharma Giant a Tech Startup Makeover
This shows how we’re using data and digital to reimagining medicine. If successful, this could open up the entire area of digital therapeutics.
Biotech VC Down 20% in US as Policies Drive Away Foreign Investors, BIO Says
Reforms to a US national security regulation are putting off foreign investors and driving down VC investment in the biotech space by as much as 20 percent, says BIO’s David Thomas.
Investor Survey: US Leads Global Healthcare Innovation, but China to Catch Up by 2025
According to a survey of 53 China-focused life science investors, 79% of the respondents believe the US is the current global leader in innovation for life science while only 15% picked China. But fast forward six years to expectations for 2025, the vote was split evenly between the two countries at about 48% each, a big turnaround.
Antimicrobial resistance: Workable business models for AMR innovation
Many antibiotics are no longer effective. Every year, an estimated 33,000 people die from resistant agents in the EU. More and more multiresistant strains arise across the globe and the list of last resort antibiotics gets smaller, which is why the United Nations has named antibiotic resistance the "biggest and most urgent global health threat."